MENU

EQ Stock Equillium (EQ, $1.02) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 26, 2025

A.I.dvisor
at Tickeron.com
Loading...
EQ - Equillium
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $1.02
Daily change: +$0.0856 (+9.16%)
Daily volume: 310.6K
Capitalization: $61.8M
Industry: Biotechnology

This is a Bullish indicator signaling EQ's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 40 similar cases where EQ's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

EQ in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 07, 2025

EQ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 44 cases where EQ's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EQ's RSI Indicator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where EQ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 26, 2025. You may want to consider a long position or call options on EQ as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EQ just turned positive on November 26, 2025. Looking at past instances where EQ's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where EQ advanced for three days, in of 252 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

EQ moved below its 50-day moving average on November 04, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EQ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EQ entered a downward trend on November 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.776) is normal, around the industry mean (27.168). P/E Ratio (0.000) is within average values for comparable stocks, (52.496). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.897). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (8.857) is also within normal values, averaging (334.447).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EQ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EQ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
EQ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. EQ showed earnings on November 13, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a developer of products for severe immune-inflammatory disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2223 Avenida De La Playa
Phone
+1 858 240-1200
Employees
44
Web
https://www.equilliumbio.com